Phase II I-SABR
Phase II I-SABR: Stereotactic Ablative Radiotherapy ± Nivolumab for Untreated Early-Stage or Isolated Lung Parenchymal Recurrent Node-Negative NSCLC

Released: September 20, 2023

Activity

Progress
1
Course Completed